EGFR and esophageal cancer: Phase 1 data for MRG003, a fully human anti-EGFR IgG1 antibody conjugated to monomethyl auristatin E stabilized disease in an EGFR-expressing esophageal cancer patient that remains on treatment at 12 weeks (57).